TITLE

Flouroquinolones compared with β-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials

AUTHOR(S)
Karageorgopoulos, Drosos E.; Giannopoulou, Konstantina P.; Grammatikos, Alexandros P.; Dimopoulos, George; Falagas, Matthew E.
PUB. DATE
March 2008
SOURCE
CMAJ: Canadian Medical Association Journal;3/25/2008, Vol. 178 Issue 7, p845
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The presumed superiority of newer fluoroquinoslones for the treatment of acute bacterial sinusitis is based on laboratory data but has not yet been established on clinical grounds. Methods: We performed a meta-analysis of randomized controlled trials comparing the effectiveness and safety of fluoroquinolones and β-lactams in acute bacterial sinusitis.Results: We identified 8 randomized controlled trials investigating the newer "respiratory" fluoroquinolones moxifloxacin, levofloxacin and gatifloxacin. In the primary effectiveness analysis involving 2133 intention-to-treat patients from 5 randomized controlled trials, the extent of clinical cure and improvement did not differ between fluoroquinolones and β-lactams (odds ratio [OR] 1.09, 95% confidence interval [CI] 0.85--1.39) at the test-of cure assessment, which varied from 10 to 31 days after the start of treatment. Fluoroquinolones were associated with an increased chance of clinical success among the clinically evaluable patients in all of the randomized controlled trials (OR 1.29, 95% CI 1.03--1.63) and in 4 blinded randomized controlled trials (OR 1.45, 95% CI 1.05--2.00). There was no statistically significant difference between fluoroquinolones and amoxicillin--clavulanate OR 1.24, 95% CI 0.93--1.65). Eradication or presumed eradication of the pathogens isolated before treatment was more likely with fluoroquinolone treatment than with &beat;-lactam treatment (OR 2.11, 95% CI 1.09--4.08). In the primary safety analysis, adverse events did not differ between treatments (OR 1.17, 95% CI 0.86--1.59). However, more adverse events occurred with fluoroquinolone use than with β-lactam use in 2 blinded randomized controlled trials. The associations described here were generally consistent when we included 3 additional studies involving other fluoroquinolones (ciprofloxacin and sparfloxacin) in the analysis. Interpretation: In the treatment of acute bacterial sinusitis, newer . . .
ACCESSION #
31315864

 

Related Articles

  • Aqueous Penetration of Gatifloxacin and Levofloxacin into the Rabbit Aqueous Humor Following Topical Dosing. Levine, Jason M.; Noecker, Robert J.; Lane, Lisa C.; Snyder, Robert W.; Rapedius, Markus; Blanchard, James // Journal of Ocular Pharmacology & Therapeutics;Jun2004, Vol. 20 Issue 3, p210 

    The aqueous penetration of the commercial preparations of the fluoroquinolone antibiotics ofloxacin, ciprofloxacin, levofloxacin, and gatifloxacin were compared following topical dosing in a rabbit model. Levofloxacin achieved the highest aqueous concentrations, with a mean aqueous level of...

  • SINUS TISSUE CONCENTRATION OF MOXIFLOXACIN AFTER A SINGLE ORAL DOSE. Dinis, Paulo Borges; Maria Conceiç, ão; Silva, Nuno; Martins, Maria Luz; Morais, José Guimarães // Annals of Otology, Rhinology & Laryngology;Feb2004, Vol. 113 Issue 2, p142 

    Moxifloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial rhinosinusitis. In order to assess its distribution pattern into the paranasal sinuses, and specifically to evaluate how the histopathologic changes associated with chronic inflammation affect its...

  • Staphylococcus aureus Is a Major Pathogen in Acute Bacterial Rhinosinusitis: A Meta-Analysis. Payne, Spencer C.; Benninger, Michael S. // Clinical Infectious Diseases;11/15/2007, Vol. 45 Issue 10, pe121 

    Background. Acute bacterial rhinosinusitis is a common health problem in the United States. Appropriate recommendations for the treatment of acute bacterial rhinosinusitis are based on the prevalence and expected antimicrobial susceptibilities of specific pathogens. Methods. A meta-analysis was...

  • The Lifecycle of Cipro. Shalo, Sibyl // Pharmaceutical Executive;Aug2004, Vol. 24 Issue 8, p40 

    Focuses on the life cycle of ciprofloxacin. Indications of the drug; Sales of the drug; Four tablet dosages.

  • Evidence-based recommendations for antimicrobial nasal washes in chronic rhinosinusitis. Elliott, Kimberly A.; Stringer, Scott P. // American Journal of Rhinology;Jan/Feb2006, Vol. 20 Issue 1, p1 

    Background: Chronic rhinosinusitis (CRS) refractory to medical and surgical therapy is a difficult problem for patients and physicians. Topical antimicrobial nasal irrigations are commonly used for treatment with great variation in methodology and without clear scientific support for current...

  • Current Management of Acute Bacterial Rhinosinusitis and the Role of Moxifloxacin. Anon, Jack B. // Clinical Infectious Diseases;7/15/2005 Supplement, Vol. 41, pS167 

    Episodes of acute rhinosinusitis are common among adults and are associated with a significant amount of morbidity. The symptoms of rhinos inusitis are nasal drainage, congestion, and sinus pressure. A bacterial sinus infection is more likely if these symptoms worsen after 5-7 days or do not...

  • ANTIBIOTICS FOR ACUTE MAXILLARY SINUSITIS IN ADULTS. Hickner, John M. // Journal of Family Practice;Apr1998, Vol. 46 Issue 4, p281 

    This article discusses the effectiveness of antibiotics in the treatment of acute maxillary sinusitis in adults. The study was a Dutch meta-analysis and the inclusion criteria were randomized, double blinded and placebo controlled trials of acute sinusitis in subjects older than 10 years old....

  • Çocuklarda Sinüzit. Cengiz, Ali Bülent // Journal of Pediatric Infection / Cocuk Enfeksiyon Dergisi;May2009 Supplement, Vol. 3 Issue S1, p35 

    Sinusitis is a common disease among children. Acute bacterial sinusitis usually develops after viral upper respiratory tract infection. Acute bacterial sinusitis diagnosis in children is generally based on clinical criteria (the situation whereby the findings and symptoms of upper respiratory...

  • Efficacy and Tolerability of Moxifloxacin in Patients with Sinusitis Treated in General Practice. Elies, W.; Landen, H.; Stauch, K. // Clinical Drug Investigation;2004, Vol. 24 Issue 8, p431 

    Objective: To assess the efficacy, safety and tolerability of moxifloxacin, an 8-methoxy fluoroquinolone, in patients with respiratory tract infections (RTIs) treated in general practice in Germany. Different RTIs were analysed separately, and this paper focuses on patients with acute sinusitis....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics